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Page 3 of 27
in
se
rm
-0
04
04
27
1,
 v
er
sio
n 
1 
- 1
6 
Ju
l 2
00
9
 3 
SBP: systolic blood pressure 
SD: standard deviation 
 
Article descriptor: Risk Assessment 
 
Section headers: 
Abstract 
Introduction 
Methods 
Results  
Discussion 
References 
Tables 
Figure Legend 
Figure 
 
 
 
 
 
 
 
 
 
 
Page 4 of 27
in
se
rm
-0
04
04
27
1,
 v
er
sio
n 
1 
- 1
6 
Ju
l 2
00
9
 4 
 
ABSTRACT: 
Background: Prior studies revealed associations of environmental lead exposure with 
risks of hypertension and elevated blood pressure.  
Objectives: To examine the effect of blood lead levels on blood pressure and the 
incidence of pregnancy-induced hypertension (PIH) in the second and third trimesters of 
pregnancy. 
Methods: One thousand seventeen pregnant women were enrolled in two French 
municipalities between 2003 and 2005 for the EDEN cohort study. Blood lead concentrations 
were measured by atomic absorption spectrometry in mothers between 24 and 28 weeks of 
gestation.  
Results: PIH was diagnosed in 106 subjects (10.9%). Age, parity, weight gain, alcohol, 
smoking habits and calcium supplementation were comparable between hypertensive and non 
hypertensive women. Lead levels were significantly higher in PIH cases (2.2 µg/dl [0.11 
µmol/l] SD 1.4 µg/dl) than in normotensive patients (1.9 µg/dl [0.09 µmol/l] SD 1.2 µg/dl); 
p=0.02. Adjustment for potential confounders slightly attenuated but did not eliminate the 
significant association between blood lead levels and the risk of PIH (adjusted OR of PIH= 
3.3, 95% CI: 1.1 to 9.7). Geographic differences in lead exposure and in the incidence of PIH 
were also observed. Significant correlations were found between blood lead levels and 
unadjusted as well as adjusted systolic and diastolic blood pressures after 24 weeks of 
gestation.  
Conclusions: These findings confirm the relationship between blood lead levels at 
mid-pregnancy and blood pressure, and suggest that environmental lead exposure may play an 
etiologic role in PIH.  
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INTRODUCTION: 
Lead (Pb) is one of the most extensively studied reproductive toxicants. Several 
epidemiologic studies have demonstrated a positive association between blood lead levels and 
blood pressure among non-pregnant adults ( Nawrot et al. 2002; Schwartz 1995). The 
evidence is sufficient to infer a causal relationship of lead exposure with hypertension (Navas-
Acien et al. 2007). However the role of lead in pregnancy induced hypertension (PIH) 
remains unclear.   
PIH is characterized by an increase in systolic blood pressure (SBP ≥ 140 mm Hg) 
and/or diastolic blood pressure (DBP ≥ 90 mm Hg) after 20 weeks of gestation. This disorder 
can be complicated by proteinuria, a condition corresponding to preeclampsia. PIH is 
encountered in 10% of pregnancies and is an important cause of morbidity for both mother 
and fetus (NHBPEP 2000).  
Environmental factors may have a role in this disease occurrence. While some studies 
failed to find a relationship between lead concentrations in cord blood and preeclampsia 
(Angell and Lavery 1982), several authors demonstrated higher levels of lead, cadmium (Cd), 
and manganese (Mn) in blood of hypertensive or preeclampsia patients, compared to 
normotensive women ( Dawson et al. 2000; Kosanovic et al. 2002; Rothenberg et al. 1999; 
Vigeh et al. 2004). Other elements such as zinc and selenium were reported to be reduced in 
hypertensive pregnant women (Dawson et al. 1999; Rayman et al. 2003).  
Blood lead levels increase during pregnancy, from 24 weeks of gestation until 
delivery, because of increased gastrointestinal absorption and because of an increase in bone 
turnover in this period ( Hertz-Picciotto et al. 2000; O'Flaherty et al. 1995). Several 
mechanisms may contribute to the pathogenesis of lead-induced hypertension: increases in 
endothelin and thromboxane production; inhibition of vascular smooth muscle ATPases; 
oxidation of endogenous nitric oxide by reactive oxygen species; and decrease in glomerular 
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filtration rate of the kidneys with increase in the rennin - angiotensin II - aldosterone activity 
(Gonick and Behari 2002; Vaziri and Khan 2007; Vaziri and Sica 2004). Interactions between 
lead and other elements are possible since oxidative stress produced by lead, cadmium or 
manganese may be counterbalanced by the anti oxidative properties of manganese or 
selenium ( Anastasakis et al. 2008; Campagna et al. 2000; Huel et al. 2000; Vaziri and Sica 
2004; Verity 1999). 
In the current study, we examined the relationship between PIH and circulating blood 
lead, cadmium, manganese and selenium concentrations in a non-selected population of 
pregnant women. 
 
METHODS: 
The study population included the first 1,017 pregnant women enrolled in the EDEN 
mother-child cohort study (Drouillet et al. 2008). The number of subjects needed for the study 
was based on a 10% prevalence of PIH and an estimated relative risk for PIH = 2.0. No other 
factors influenced the inclusion process. 
All women aged from 18 to 45 years who presented before 24 weeks of gestation for 
prenatal care at two maternity wards in Poitiers (western France) and Nancy (eastern France) 
were enrolled if they were able to read and write French, and were not planning to move out 
of the region. We also excluded women who had multiple gestations or a history of diabetes. 
Among women who fulfilled these criteria, 55% agreed to participate. The study was 
approved by the Ethic Committee of Bicêtre Hospital (November 2002). All participants 
provided informed consent consistent with policies of the Institutional Review Board.  
We collected maternal blood samples between 24 and 28 weeks of gestation, just after the 
recruitment was validated by the study midwife. We determined blood lead, cadmium and 
manganese concentrations by electrothermal atomic-absorption spectrometry (model 4100 
Page 7 of 27
in
se
rm
-0
04
04
27
1,
 v
er
sio
n 
1 
- 1
6 
Ju
l 2
00
9
 7 
ZL, Perkin-Elmer) with Zeeman background correction as previously described (Fréry et al. 
1993; Huel et al. 1986; Mergler et al. 1996). We measured selenium by standard fluorometric 
method as described by Lee et al. (Lee et al. 1995). We calculated values as means of two 
analyses of each sample expressed in µg/dl. Internal and external quality-control procedures 
yielded consistently satisfactory results. The limit of detection for the blood lead 
measurements was 0.5 µg/dl. We assigned a value of 0.5 divided by two for values below the 
limit of detection. Of the measured values of blood lead, 2.7% were below the limit of 
detection.   
Gestational age was based on last menstrual period and/or ultrasound-based estimated 
date of conception. We divided pregnancy into three periods: P1 before 24 weeks, P2 between 
24 and 36 weeks, and P3 after 36 weeks of gestation. This choice was mainly founded on 
scientific data regarding the incidence of PIH in second half of pregnancy and its frequency 
with increasing gestational age (Groom et al. 2007).   
We measured maternal blood pressure during routine monthly visits with the subject in supine 
position, using a standard mercury sphygmomanometer. Measures also were taken by the 
study midwife between 24 and 28 weeks using a different (semi-automated) device, with two 
measurements averaged to determine the values for that visit. All measurements taken within 
each period of gestation (P1, P2, and P3) were averaged to determine the values for SBP and 
DBP assigned to each period.Women were classified as having PIH based on SBP ≥ 140mm 
Hg or DBP ≥ 90mm Hg at two or more visits after the 22nd week of gestation, such that the 
elevated measures could have occurred during or across any of the three periods, and no 
diagnosis of PIH was made before 24 weeks.  
We gathered medical and reproductive histories, clinical follow-up and delivery data from 
obstetrical records. Additional risk factors for PIH were obtained using the study 
questionnaires administered by trained interviewers during a structured interview. These 
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included basic socio-economic information, educational level, cigarette and alcohol use 
before and during pregnancy. Dietary information on coffee and tea consumption, and intake 
of calcium, vitamins or iron supplements was also recorded. We classified socio-economic 
status based on household monthly income and categorized it into three levels (high if > 3,000 
EUR; medium between 1,500 and 3,000 EUR; and low if < 1,500 EUR). We also divided 
education status into two levels (high if ≥ 12 years, and low if < 12 years). For the analysis of 
main effects, all variables (except for hematocrit) were categorized. 
Statistical data analysis was performed using SAS software v9.1.3 (SAS Institute Inc., Cary, 
NC, USA). We evaluated variables for normality and for outliers. Because of skewed 
distributions, lead, cadmium, manganese and selenium blood levels were transformed into 
their decimal logarithms and subsequent geometric means were calculated. Continuous 
variables were summarized by calculating the mean and standard deviation. Comparisons of 
means or proportions were performed by chi-square or Student t-test as appropriate. Cochran-
Armitage was used for trend analysis. We obtained adjusted odds ratios by means of 
multivariable logistic regression analysis with PIH as the dependent variable. We based 
selection criteria for variables on the literature regarding risk factors of PIH. Besides all 
elements measured, adjustment variables included maternal age, parity, hematocrit, body-
mass index, pregnancy weight gain, gestational diabetes, educational level, socio-economic 
status, geographical residence (maternity ward), smoking status and alcohol consumption 
before and during pregnancy. Although we used stepwise procedure to ascertain percentage of 
variance attributable to selected variables, relevant risk factors were forced into the final 
model. We tested interaction terms between blood lead levels (as a continuous variable) and 
other maternal variables with a significance level reduced to 0.005 (according to the 
Bonferroni method). Otherwise, a P value of less than 0.05 was considered to indicate 
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statistical significance. Pearson partial correlations were calculated between blood lead levels 
and SBP and DBP during the three periods of pregnancy.  
 
RESULTS: 
Among the 1,017 considered women, we excluded 31 records (3.0%) because of 
insufficient sample volumes or analytical problems in lead measurements and 15 records 
(1.5%) because of chronic hypertension under treatment before pregnancy. This left a study 
group of 971 pregnant women. Mothers’ mean age was 29.3 ± 4.9 years. PIH occurred in 106 
(10.9%) women and was complicated by proteinuria (preeclampsia) in 20 (2.1%) cases.  
 Table 1 summarizes the characteristics of the cohort in relation to PIH occurrence. 
When compared with normotensive group, women who developed PIH presented with a 
higher body mass index before pregnancy (21.9% versus 6.3%, p<0.001) and a higher 
hematocrit (35.2% versus 34.6%, p=0.02). They were also more likely to be diagnosed with 
gestational diabetes (17.0% versus 5.9%, p<0.001) and have a premature delivery (prior to 
completing 36 weeks of gestation, 13.2% versus 5.0%, p<0.001). The incidence of PIH was 
significantly higher in Nancy than in Poitiers (63.2 versus 36.8% of PIH patients, p<0.001; 
respectively). PIH was also negatively associated with birth-weight. There were very few 
missing covariate data (less than 3.8% in the PIH group and less than 5.2% among women 
without PIH for most of the variables studied). 
Mean blood lead concentration in the PIH group (2.2 ± 1.4 µg/dl; Range: 0.2 – 8.5 
µg/dl) was significantly higher than in women without PIH (1.9 ± 1.2 µg/dl; Range: 0.2 – 6.9 
µg/dl) (p=0.02). Mean manganese concentration was slightly (but not significantly) higher in 
PIH women. Cadmium and selenium blood concentrations were comparable between groups 
(Table 2).  
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The frequency of PIH was lowest among women whose blood lead concentrations 
were in the lowest quartile (7.7%) and was significantly greater in the second (10.7%), third 
(11.1%), and fourth exposure quartiles (13.1%) (p=0.03 for trend). The unadjusted odds ratio 
(OR) of PIH associated with an increase of 1 µg/dl in maternal blood lead was 3.5 (95% CI: 
1.4 to 8.9). 
Adjustment for a range of characteristics and elements (cadmium, manganese and selenium 
blood concentrations, hematocrit, maternal age, body-mass index, parity, gestational diabetes, 
education and socio-economic level, smoking status and geographic residence) slightly 
attenuated but did not eliminate the significant association between blood lead levels and the 
risk of PIH (Table 3). Adjusted OR of PIH for an increase of 1 µg/dl in maternal blood lead 
was estimated at 3.3 (95% CI: 1.1 to 9.7). No significant interactions were observed between 
blood lead levels and any of the other elements and the maternal characteristics in predicting 
the risk of PIH (all interaction p-values > 0.05). Furthermore, excluding women with 
preeclampsia (n=20) did not substantially alter the association between blood lead level and 
PIH (adjusted OR= 3.1; 95% CI: 1.0 to 10.0).      
 
When stratified by parity (Table 4), blood lead levels were higher in multiparous 
women than nulliparous women (2.0 ± 1.2 µg/dl versus 1.8 ± 1.3 µg/dl, respectively; 
p=0.003). The adjusted OR for PIH also was higher in multiparous women (OR= 4.6; 95% 
CI: 1.0 to 21.6) than nulliparous women (OR= 2.9; 95% CI: 0.6 to 15.7), but there was no 
interaction between parity and blood lead (p=0.46). 
  
Log-transformed blood lead at mid-pregnancy was significantly correlated with both 
systolic and diastolic blood pressures at 24 – 36 weeks of gestation (r=+0.08; p=0.03 and 
r=+0.07; p=0.03, respectively), and after 36 weeks of gestation (r=+0.09; p=0.03 and r=+0.08; 
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p=0.03, respectively). Figure 1 illustrates correlation between residuals of the linear 
regression of maternal blood lead and systolic blood pressure at 24 – 36 weeks. Lead 
concentrations accounted for approximately 5% of the total unexplained variance obtained by 
linear models. Each decimal-log increase in blood lead was associated with an increase of 3.5 
mm Hg in SBP and of 2.5 mm Hg in DBP during the second half of pregnancy.  
        
DISCUSSION: 
We found that the adjusted risk of PIH was associated with maternal blood lead levels 
in mid-pregnancy. This risk was doubled in the highest quartile as compared to the lowest 
quartile of lead distribution. There was no strong evidence of an interaction between lead and 
cadmium, manganese, selenium, or other factors associated with the risk of PIH. The risk of 
PIH increased with increasing absolute values of mid-pregnancy blood lead in a “dose-
response” pattern. A positive correlation was particularly found with systolic blood pressure 
at 24 – 36 weeks that persisted after 36 weeks. All these findings suggest that blood lead level 
may be one of the causal factors of PIH. 
Evidence that lead increases the circulating levels of endothelin, a vaso-active 
substance secreted by endothelial cells has been reported (Gonick and Behari 2002). Lead is 
also reported to reduce levels of vasodilator substances such as plasma nitric oxide and 
endothelial-derived relaxation factor; this reduction is due to a lead-mediated increase in 
reactive oxygen species (Carmignani et al. 2000; Gonick and Behari 2002; Gonick et al. 
1997). Inhibition of membrane ATPases by this metal also leads to increased intracellular 
calcium ions and vasoconstriction (Moreau et al. 1988). Furthermore, a demonstrable 
inhibitory effect of lead on blood enzymes such as delta-aminolevulinic acid dehydratase 
activity was found at a low threshold of lead exposure, ranging from 3.2 to 4.8 µg/dl 
(Campagna et al. 1999; Telisman et al. 2004). From the above arguments, it may be 
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hypothesized that environmental exposure to lead increases the risk of PIH by inducing 
vasoconstriction and placental ischemia or by a direct toxicity on the endothelial cell and the 
renal function.  
Our findings are consistent with those from previous studies showing a relationship 
between blood lead levels and PIH. However, most of these reports analysed lead 
concentrations late in pregnancy, either from maternal prenatal red blood cells (Dawson et al. 
2000), from umbilical cord (Rabinowitz et al. 1987), amniotic fluid (Dawson et al. 1999), or 
even from maternal blood within 24 hours after the delivery (Vigeh et al. 2004; Vigeh et al. 
2006). Our study did not involve serial measurements of blood lead levels throughout 
pregnancy. However, the optimal period for such measurement would be in the second 
trimester (24 weeks of gestation), at the beginning of a potential pathological change in blood 
pressure. Moreover, models on lead variation during pregnancy described a constant increase 
in blood lead levels from 24 weeks of gestation until delivery (O'Flaherty et al. 1995). Indeed, 
longitudinal analyses showed that maternal blood lead concentrations upon entering prenatal 
care (average of 13.5 weeks) were not associated with PIH, whereas higher lead levels during 
the second trimester were related to PIH (Sowers et al. 2002).  
  
Our analysis of correlations between blood lead concentrations and SBP and DBP at 
24 – 36 weeks and after 36 weeks of gestation was consistent with previous studies on 
essential hypertension (Batuman et al. 1983). Recent reviews suggest a weak but dependable 
association between lead levels and blood pressure. The increase in SBP is estimated between 
0.8 and 2.0 mm Hg for each 1 µg/dl increase in blood lead (Hertz-Picciotto and Croft 1993; 
U.S.EPA 2006). Women with chronic hypertension were excluded from our study because of 
risks of bias associated to prior treatment with anti hypertensive drugs. This exclusion might 
have attenuated the correlation between blood lead and blood pressure.   
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Manganese blood level was not significantly associated with PIH in this study, 
although there was some evidence of a possible weak association. The underlying 
mechanisms of manganese-induced hypertension are probably independent from gestational 
age. The decrease in blood manganese with intrauterine growth restriction might obscure any 
other pathological effect (Vigeh et al. 2008). Cadmium also was not significantly associated 
with PIH in the present model. This finding may be related to relatively low levels of 
cadmium observed in this cohort. These reduced levels were probably due to the low 
prevalence of smoking, which is the main environmental source of cadmium (Bonithon-Kopp 
et al. 1986).  Interaction between selenium and lead concentrations were not significant and 
the putative protective effect of selenium through anti-oxidative properties was not confirmed 
in this study. 
Hematocrit levels are usually elevated in pregnancy hypertensive disorders (Goldstein 
et al. 2000). This may be due to a lower water balance index correlated to stroke volume or to 
a lower venous capacitance in hypertensive patients (Aardenburg et al. 2005). Hematocrit 
increases automatically increase blood lead which is concentrated in red blood cells. No 
statistical interaction was found between blood lead and hematocrit, but confounding can not 
be ruled out.  
Body-mass index was strongly associated with PIH. This finding is consistent with previous 
reports (Hrazdilova et al. 2001; Vigeh et al. 2006). A “dose-response” relationship has also 
been observed, thus body-mass index before pregnancy should be considered in all models 
including PIH. Gestational diabetes effect on PIH was limited in the multivariate regression 
analysis probably because of its association with increased body-mass index. Age and parity 
were not significant covariates in this study. A trend of increasing blood pressure with age is 
usually reported for diastolic blood pressure, but the restricted age range (i.e., 18 – 45 yr) and 
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limited number of women above 40 years in the present study may have reduced our ability to 
highlight an age effect on PIH.  
As to parity, high levels of blood lead observed in multiparous women of this study 
may have contributed to an increase in the frequency of PIH in this group, thus reducing the 
difference usually observed in the incidence of PIH and preeclampsia depending on parity. 
Moreover, data obtained from systematic ambulatory monitoring in a large sample of 
normotensive pregnant women indicate the lack of differences in blood pressure according to 
parity (Ayala and Hermida 2001) 
Finally, PIH frequency was higher in Nancy than in Poitiers. A separate analysis (not 
shown) revealed higher blood lead levels in Nancy (2.0 ± 1.3 µg/dl) than in Poitiers (1.8 ± 1.1 
µg/dl); p<0.001. Thus a major difference in the incidence of PIH between these two regions 
might have been their history of environmental exposure to chemical pollutants. Blood lead 
level primarily reflects recent exposure, although a part of lead in blood may originate from 
lead stored in bone, particularly during pregnancy (Gulson et al. 1997). Since bone lead has a 
half-life of years to decades, the higher blood lead levels observed in eastern versus western 
region reflect differences in current exposure, but may also reflect some differences in past 
exposure, or both. Hence, the relationship between blood lead and blood pressure may be 
mediated by the contribution of bone lead to blood lead, placing a larger amount of 
bioavailable lead into tissues and organs that affect blood pressure (Rothenberg et al. 1999). 
The main sources of measurements errors of blood pressure are the inaccuracy of 
measurement methods and the intra-individual variability of blood pressure. We attempted to 
minimize these effects by averaging all blood pressure measurements available in the 
obstetrical files.        
Although the association between blood lead levels and PIH persisted in the 
multivariate analysis, it is also possible that it reflects residual confounding due to 
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unmeasured confounders. The geographic residence is a general covariate and residual 
confounding by this variable cannot be ruled out. However, if this residual confounding 
explained the association found in the multivariate analysis, it is likely that an interaction 
between geographic residence and blood lead levels would have been observed. Moreover, 
blood lead concentration may be a better estimate of maternal environmental exposure than 
external indicators, and its use as a continuous variable in the regression model limits the risk 
of residual confounding. 
Pregnancy-induced hypertension remains a multifactorial disease with unclear 
aetiology, which could compromise maternal and newborn reproductive outcomes. We 
identified a significant association between maternal blood lead levels in mid-pregnancy and 
blood pressure. Our findings that lead may have an etiologic role in PIH, even at low levels of 
environmental exposure, suggest that it may be appropriate for public health organizations to 
consider lowering the upper limit of “acceptable” blood lead levels in pregnant women, which 
is currently at 10 µg/dl.  
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Tables 
Table 1. Baseline characteristics according to PIH occurrence among 971 pregnant women 
with no history of chronic hypertension. 
 PIH (mean or %) No PIH (mean or %) P Value 
Maternal age – yr    
< 25 19.8 17.6 
25 – 34 64.2 68.2 
≥ 35 16.0 14.2 
   N 106 865 
 
0.70 
Years of education    
≥ 12 yr 64.2 66.2 
< 12 yr 30.2 29.0 
Unknown 5.7 4.7 
   N 106 865 
 
0.87 
Socio-economic status    
High 25.7 25.5 
Medium 52.4 55.5 
Low 21.9 19.0 
   N 105 851 
 
0.76 
Geographic residence    
Poitiers (Western) 36.8 58.6 
Nancy (Eastern) 63.2 41.4 
   N 106 865 
 
< 0.001 
Hematocrit – % a,b  35.2 (2.5) 34.6 (2.6) 
   N 105 842 
0.02 
BMI before pregnancy – Kg/m2    
< 25 53.3 76.2 
25 – 29.9 24.8 17.5 
≥ 30 21.9 6.3 
   N 105 835 
 
< 0.001 
Weight gain during pregnancy – kg a  13.4 (6.5) 13.4 (4.6) 
   N 104 834 
0.92 
Gestational diabetes    
No 83.0 94.1 
Yes 17.0 5.9 
   N 106 851 
 
< 0.001 
Parity    
Nulliparous 42.5 44.3 
Multiparous 57.5 55.7 
   N 106 848 
 
0.71 
Smoking during pregnancy – cig/day    
0 72.6 71.7 
≥ 1 27.4 28.3 
1 – 9 19.6 22.2 
≥ 10 7.8 6.1 
 
0.86 
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   N 102 820 
Alcohol consumption before pregnancy    
No 28.2 28.7 
Yes 71.8 71.3 
   N 103 849 
 
0.90 
Iron/calcium supplementation    
No 2.8 3.9 
Yes 61.3 60.1 
Unknown 35.9 36.0 
   N 106 865 
 
0.95 
Premature delivery (before 37 wk)    
No 86.8 95.1 
Yes 13.2 5.0 
   N 106 851 
 
<0.001 
Neonate weight – gr a  3126.7 (719.9) 3299.0 (493.6) 
   N 106 844 
0.02 
Neonate gender    
Male 58.5 52.9 
Female 41.5 47.1 
   N 106 849 
 
0.28 
a
 values are means (SD).  
bHematocrit levels were measured concomitantly with metals between 24 and 28 gestational 
weeks 
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Table 2. Distribution of elements levels in maternal blood at mid-pregnancy, according to PIH 
occurrence. 
PIH (n=106) No PIH (n=865)  
Mean (SD) GM Mean (SD) GM 
P Valuea 
Lead (µg/dl) 2.2 (1.4)b 1.9 1.9 (1.2) 1.6 0.02 
Cadmium (µg/l) 0.9 (0.5) 0.8 0.9 (0.6) 0.7 0.08 
Manganese (µg/l) 11.8 (6.3) 10.6 10.6 (4.5) 9.6 0.06 
Selenium (µg/l) 98.8 (29.0) 93.3 98.6 (26.2) 95.5 0.76 
a
 t-test on the log transformed variables 
b To convert values for lead to micromoles per liter, multiply by 0.0483. 
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Table 3. Odds ratios for PIH, according to maternal blood lead distribution and overall 
outcome characteristics. 
 
Unadjusted Analysis Adjusted Analysisa 
 
OR (95% CI) P value OR (95% CI) P value 
Log (Pb)b  3.49 (1.37 – 8.87) 0.009 3.29 (1.11 – 9.74) 0.03 
- Q1c (referent) 1.0  1.0  
- Q2 1.55 (0.78 – 3.11) 0.94 1.84 (0.77 – 4.41) 0.84 
- Q3 1.61 (0.78 – 3.31) 0.81 2.07 (0.83 – 5.13) 0.50 
- Q4 2.19 (1.09 – 4.41) 0.06 2.56 (1.05 – 6.22) 0.09 
Number of observations used in adjusted analysis: 720; Convergence criterion satisfied; R2=15.7% 
 
a
 Adjusted for maternal age, cadmium, manganese and selenium blood levels, hematocrit, 
parity, body-mass index, gestational diabetes, educational level, socio-economic status, 
geographical residence, and smoking status during pregnancy. 
b
 Log-transformed maternal blood lead used as a continuous variable 
c
 Quartiles of maternal blood lead distribution: Q1 (< 1.20 µg/dl); Q2 (1.20 – 1.70 µg/dl); Q3 
(1.71 – 2.30 µg/dl); and Q4 (> 2.30 µg/dl). 
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Table 4. Odds Ratios for PIH according to parity, per unit increase in blood lead level. 
 PIH incidence Unadjusted OR (95% CI) Adjusted ORa (95% CI) 
Nulliparous 10.7 % 1.8 (0.5 – 6.6) 2.9 (0.6 – 15.7)  
Multiparous 11.4 % 3.7 (1.1 – 12.3) 4.6 (1.0 – 21.6) 
 
a
 Adjusted for maternal age, cadmium, manganese and selenium blood levels, hematocrit, 
body-mass index, gestational diabetes, educational level, socio-economic status, geographical 
residence, smoking status and alcohol consumption before pregnancy. 
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Figures 
Figure 1. Scatter plot of the residuals for maternal blood Lead and systolic blood pressure 
between 24 and 36 weeks (SBP2) after controlling for the effect of variables listed in the 
logistic model in table 3.  
 
 
This figure illustrates the correlation between residuals of the linear regression of the two 
variables on the partialled variables. In the 95% and 70% prediction ellipses, the major axis 
length is significantly larger than the minor axis length, indicating a partial correlation 
between maternal blood lead and SBP2. 
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